News & Insights

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Functional, Sensorimotor, and Cognitive Outcomes Following Unilateral MCAO in Rats

Behavioral and pharmacological characterization of the isosorbide dinitrate model of headache in male and female rats

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

Society for Neuroscience 2023

This company is using AI to develop drugs. Schizophrenia is its first target

World Wellbeing Week 2023: Celebrating drug discovery innovation

How AI Will Make Our Lives Better (And Worse)

AI-Discovered Drug Shows ‘Enormous Potential’ to Treat Schizophrenia: ‘Real Need for Better Treatment’

PsychoGenics’ SmartCube Prompts a Reevaluation of CNS Drug Discovery

PsychoGenics Launches eCube AI Platform for Drug Discovery

PsychoGenics Introduces eCube, an AI-Driven Platform for Drug Discovery in Neuropsychiatric Disorders

PsychoGenics Launches AI Platform to Revolutionize Drug Discovery

Let’s Find the Right Solution Together

Quick Links

Contact

Address

Email

Phone

Fax